This activity has expired. Credit is no longer available.
This activity was supported by educational grants from AbbVie Inc.; Celgene Corporation; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Recent Advances in the Treatment of Newly Diagnosed Multiple Myeloma
Josh Epworth, ARNP
Seattle Cancer Care Alliance
Edward Libby, MD
University of Washington
Watch as two experts in the field of multiple myeloma (MM) interpret data on current and novel treatments, discuss how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluate the use of minimal residual disease testing in patients with MM.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |
in collaboration with
  |